Theridat

**Theridat** appears to be an investigational targeted radiopharmaceutical theranostic program associated with Scintomics for **adrenocortical cancer**. Publicly available information is very limited, but the name has been cited by company materials listing Scintomics' pipeline of functional diagnostics and radiotherapeutics alongside other theranostic assets. The specific radioactive payload, molecular target, mechanism of tumor targeting, formulation details, route of administration, and clinical development details are not clearly disclosed in readily accessible sources, so its precise mechanism of action cannot be stated with confidence.

Brand names

Theridat